Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure - a case report and brief review of the literature

International Journal of Infectious Diseases

Volumn 14, Issue 6, 2010, Pages

  Rybniker, Jan ^a   Goede, Valentin ^a   Mertens, Jessica ^a   Ortmann, Monika ^a   Kulas, Wolfgang ^b   Kochanek, Matthias ^a   Benzing, Thomas ^a   Arribas, José R ^c   Fätkenheuer, Gerd ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Nephrologisches Zentrum Mettmann   (Germany)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Fluconazole; HIV; Miltefosine; Pentamidine; Renal failure; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ATAZANAVIR; FLUCONAZOLE; INDINAVIR; MILTEFOSINE; PENTAMIDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG RESPONSE; DRUG WITHDRAWAL; DUODENITIS; EPIGASTRIC PAIN; EROSIVE GASTRITIS; GASTROSCOPY; GLOMERULONEPHRITIS; HEMODIALYSIS; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KIDNEY BIOPSY; LEISHMANIA DONOVANI; LONG TERM CARE; MALE; NAUSEA; OROPHARYNX CANDIDIASIS; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; RELAPSE; SECONDARY PREVENTION; SKIN DEFECT; STOMACH BIOPSY; TASTE DISORDER; VISCERAL LEISHMANIASIS; VOMITING;

ADMINISTRATION, ORAL; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIPROTOZOAL AGENTS; DRUG THERAPY, COMBINATION; FLUCONAZOLE; HIV SEROPOSITIVITY; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PENTAMIDINE;

EID: 77952321515     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.06.010     Document Type: Article

References (16)

1. Alvar J., Aparicio P., Aseffa A., Den Boer M., Canavate C., Dedet J.P., et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21 (2008) 334-359
2. Lyons S., Veeken H., and Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health 8 (2003) 733-739
3. Bentwich Z. Concurrent infections that rise the HIV viral load. J HIV Ther 8 (2003) 72-75
4. Rosenthal E., Marty P., del Giudice P., Pradier C., Ceppi C., Gastaut J.A., et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 31 (2000) 1093-1095
5. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 97 Suppl 1 (2003) 135-142
6. Ritmeijer K., Dejenie A., Assefa Y., Hundie T.B., Mesure J., Boots G., et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 43 (2006) 357-364
7. Schraner C., Hasse B., Hasse U., Baumann D., Faeh A., Burg G., et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 40 (2005) e120-e124
8. Rihl M., Stoll M., Ulbricht K., Bange F.C., and Schmidt R.E. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in an HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect 53 (2006) e25-e27
9. Lachaud L., Bourgeois N., Plourde M., Leprohon P., Bastien P., and Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 48 (2009) e16-22
10. Delgado J., Macias J., Pineda J.A., Corzo J.E., Gonzalez-Moreno M.P., de la Rosa R., et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg 61 (1999) 766-769
11. Conte Jr. J.E., Upton R.A., and Lin E.T. Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. J Infect Dis 156 (1987) 885-890
12. Alrajhi A.A., Ibrahim E.A., De Vol E.B., Khairat M., Faris R.M., and Maguire J.H. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346 (2002) 891-895
13. Sundar S., Singh V.P., Agrawal N.K., Gibbs D.L., and Murray H.W. Treatment of kala-azar with oral fluconazole. Lancet 348 (1996) 614
14. Sundar S., Gupta L.B., Makharia M.K., Singh M.K., Voss A., Rosenkaimer F., et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 93 (1999) 589-597
15. Pintado V., Martin-Rabadan P., Rivera M.L., Moreno S., and Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80 (2001) 54-73
16. Lehmann C., Jung N., Hofmann A., Cornely O.A., Wyen C., Fatkenheuer G., et al. Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression. Curr HIV Res 6 (2008) 555-559